BlueRock Therapeutics

ENB Therapeutics is a pioneering biopharmaceutical company based in New York, NY, dedicated to overcoming immunotherapy resistance in cancer treatment. Their innovative approach targets the tumor microenvironment, utilizing two unique mechanisms to empower the body's immune system in effectively combating drug-resistant cancers.

By developing small molecules that turn off a common switch activating pro-cancer components of the tumor microenvironment, ENB Therapeutics aims to transform "cold" tumors into "hot" tumors, enabling immune cells to infiltrate and kill cancer cells. Additionally, their therapies promote the formation of intratumoral tertiary lymphoid organs (TLOs), which act as antibody factories and induce long-lasting anti-cancer immunity. With demonstrated preclinical efficacy in various cancer types, including melanoma, glioblastoma, and ovarian cancer, ENB Therapeutics is at the forefront of a new era in cancer therapy.

Generated from the website